Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemsidomide + Elranatamab in R/R Multiple Myeloma
NCT07280013Phase 1Recruiting
- Sponsor
- C4 Therapeutics
- Start
- Feb 2026
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of cemsidomide in multiple myeloma (MM), sponsored by C4 Therapeutics. Primary endpoint: Safety and tolerability of cemsidomide in combination with elranatamab at 28 days. Started Feb 2026; status: recruiting.
02
Drugs
cemsidomide
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07280013.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07280013.